GAITHERSBURG, Md., July 29, 2021 /PRNewswire/ — MaxCyte, Inc., (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the pricing of its upsized offering of 13,500,000 shares of common stock at an initial offering price of US$13.00 per share (the “Offering”).
MaxCyte has granted the underwriters a 30-day option to purchase up to 2,025,000 additional shares of common stock at the initial offering price per share of common stock less underwriting discounts and commissions.
The closing of the Offering is expected to occur on August 3, 2021, subject to customary closing conditions.
{iframe}https://www.prnewswire.com/news-releases/maxcyte-announces-pricing-of-upsized-offering-and-approval-to-list-on-the-nasdaq-global-select-market-301344880.html{/iframe}